Dates of Funding: 2024-2026
“Metabolic reprogramming of oligodendrocytes in intrauterine growth restriction”
Infants born following intrauterine growth restriction (IUGR) are recognized to be at risk for the development of cerebral palsy (CP). White matter injury (WMI), the histopathological correlate to CP, has been well documented in human and animal studies of IUGR. Existing literature suggests that impaired oligodendrocyte (OL) differentiation may be responsible for the WMI seen in IUGR. This project will evaluate a potential bioenergetic mechanism for impaired OL differentiation in PI-IUGR with the central hypothesis that PI-IUGR leads to metabolic reprogramming of OPCs, which results in long term impairments in differentiation and myelination. The experiments proposed in this application will evaluate this hypothesis using Agilent Seahorse technology to characterize substrate dependency, capacity, and flexibility of OPCs exposed to PI-IUGR.
Tyler Cook, PhD
Years of Funding 2024-2026
“Mechanisms of portal glucose sensing”
I am a postdoctoral fellow in the Pediatrics Department, Nutrition Division. My research goal is to understand how nutrient signals are detected and integrated into the brain to control energy balance and glucose homeostasis. I am currently funded through a T32 from the Pediatrics Nutrition Division, and I have also received a NIH/NIDDK F32 Fellowship investigating neuronal mechanisms associated with postbariatric hypoglycemia.
For my Colorado NORC pilot award, I am investigating how peripheral sensory neurons detect changes in blood glucose to maintain glucose homeostasis. Sensory neurons innervate the gastrointestinal tract and rapidly transmit nutrient signals to the brain before the nutrients even hit systemic circulation. In obesity, these sensory mechanisms likely become overwhelmed and contribute to the dysregulation of energy balance and glycemia. By understanding the mechanisms of neuronal glucose sensing, and how obesity disrupts these processes, I hope to identify new therapeutic targets for metabolic disease.
Stephanie Gilley, MD, PhD
Years of Funding: 2024-2026
“Solving a big problem for tiny babies: Digital body composition for infants”
I am an assistant professor in the Section of Nutrition, Department of Pediatrics. My research centers on understanding the earliest origins of health and disease and how we should feed infants and toddlers based on their intrauterine exposures. Body composition is an essential outcome measure to fully understand the impact of early life nutrition interventions. Despite the importance of body composition, most large research studies are limited to simple anthropometric measurements such as weight, height and BMI, limiting their impact. Major limitations to assessing body composition longitudinally in children include cost, acquisition time, radiation exposure, and/or requirement for trained personnel. Our project aims to develop a novel method for assessing body composition in infants using digital photography. Ready access to body composition will improve infant nutritional and growth monitoring and, in turn, directly impact patient outcomes.
Emily Hill, PhD, RDN
Years of Funding: 2024-2026
“Defining impact of changes in dietary intake patterns using -omics assessments within behavioral weight loss interventions”
I am a Research Instructor/Fellow and Registered Dietitian Nutritionist (RDN) with extensive training in nutrition and clinical and translational research. My research objective is to develop an independent research program that: 1) rigorously develops and tests interventions to improve adherence to evidence-based guidelines for lifestyle behaviors and 2) incorporates -omics approaches to predict and evaluate response to intervention. My current work is funded through a National Cancer Institute K99/R00 award (K99 CA287061) and builds upon a recently completed proof-of-concept trial that I implemented at the University of Colorado Cancer Center. Through these efforts, I am developing a survivorship nutrition intervention, called BfedBwell, to be integrated within the existing BfitBwell cancer exercise program. The goal is to use the Multiphase Optimization STrategy (MOST) framework to create a comprehensive program that will help adults with a history of cancer and overweight/obesity to improve diet and physical activity patterns. I am leading a 2^3 factorial trial to test three different program components alongside a core education curriculum. My Colorado NORC Pilot Award will allow me to leverage this clinical trial to collect additional biological samples and associated data necessary to evaluate the intervention through the incorporation of targeted and untargeted -omics approaches. Using these approaches, I will be able to assess change in exposure to a high-quality dietary pattern and explore associations with cardiometabolic health via integrated network analysis. Future work will include a fully-powered R01 optimization trial of the BfedBwell program and adaptation for dissemination to other settings and populations.
Matthew Olm, PhD
Years of Funding 2024-2026
"Quantifying the impact of first foods on the infant gut microbiota and immune health"
I am an Assistant Professor at the University of Colorado, Boulder. In this study, I aim to investigate how the first foods infants consume influence the development of their gut microbiome and its interaction with the immune system. Early-life diet plays a crucial role in shaping long-term health outcomes, including risks for obesity and autoimmune diseases. However, there is still a lack of evidence-based guidelines for optimal first foods. To address this, I will use metagenomic immunoglobulin sequencing (MIg-Seq) to study how different diets—specifically meat, dairy, plant-based, and control diets—affect IgA (immunoglobulin A) binding in the gut microbiota. My research will focus on how diet modulates IgA specificity and production, which in turn influences the colonization of beneficial microbes. Through this study, I hope to uncover dietary factors that promote healthy immune development and microbiome composition, with the ultimate goal of informing dietary recommendations for infants. This project builds on my expertise in microbiome research and has the potential to expand to additional study sites and populations.
Dates of Funding: 2019-2020
Transgender (trans) people have a gender identity and/or gender expression that does not align with their sex assigned at birth (SAB). Many trans people experience associated distress known as gender dysphoria. Health care disparities among trans people are prevalent, related to gender dysphoria, fears of discrimination, access to medical/surgical care and other barriers. Among the many health care disparities faced by trans people, studies have reported on decreased physical activity and healthy eating habits as well as increased tobacco smoking, alcohol use and drug use. My quality improvement project during endocrine fellowship revealed higher rates of obesity among both trans women and trans men compared to the general adult population of Colorado. Research locally and around the world tries to better understand the basis for and evaluate solutions to reduce differential health outcomes based on gender identity.
As an early career endocrinologist at the University of Colorado School of Medicine (CUSOM), my academic trajectory is to explore the impacts of obesity, aging and gender-affirming hormone therapy (GAHT, or using sex hormones of the affirmed gender) on cardiometabolic risk in trans people. My current research compares vascular endothelial function and aging in trans women and men on chronic GAHT with the same parameters in cisgender (cis) women and men, individuals whose gender identity aligns with their SAB. These data will provide preliminary data for further investigations on the effects of sex steroids in trans and cis people. My interest in trans research has a foundation in years of volunteer work within the trans and other sexual/gender minority communities. Over the years, I have also heard from trans patients about continued stigma within medicine regarding access to culturally sensitive and comprehensive care. Trans patients deserve evidence-based best practices for health care delivery, particularly in the setting of GAHT, which has been associated with weight gain and an increased risk cardiovascular disease (CVD) and venous thromboembolism in trans women and possibly trans men. Whether gonadectomy (after GAHT, based on clinical practice guidelines) affects CVD risk is yet to be determined.
In September 2017, I co-founded the UCHealth Integrated Transgender Program (ITP) with my mentor, Dr. Micol Rothman, and other specialists in psychiatry, internal medicine, gynecology and plastics and reconstructive surgery, to provide safe and comprehensive care to our trans patients during a single clinic visit within the Endocrinology Clinic. ITP also educates providers, staff and learners across the hospital system and within the community. We received a 2018 University of Colorado President’s Diversity & Inclusive Excellence Grant, the 2019 University of Colorado Hospital Medical Staff Award for Excellence in Clinical Innovation and a 2019 One Colorado Ally Award. We are collecting qualitative (e.g., patient and provider needs assessments) and quantitative (e.g., Pap test and other cancer screening compliance, hormone monitoring, body mass index [BMI] and body composition changes, laboratory trends, pre-/post-Provider Education Day knowledge differences) data. We are establishing a Community Advisory Board to engage stakeholders in developing ideas for future research collaborations and participant recruitment. I am also spearheading the creation of a registry of trans patients at UCHealth and will collect prospective data on health outcomes. Working with the Division of Plastic and Reconstructive Surgery, a new plastic surgeon will join the ITP team in Sept 2019, increasing access to gender-affirming surgery to our patients.
To learn more about trans health research, I met Dr. Guy T’Sjoen (Ghent University Hospital, Belgium) and Dr. Martin den Heijer (Amsterdam University Medical Center, the Netherlands) as part of a 2017 American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) Dr. Lewis E. Braverman Educational Fund Travel Grant. Both are endocrinologists and primary investigators of the European Network for the Investigation of Gender Incongruence (ENIGI), the first collaboration to create a multicenter, multinational, standardized treatment and follow up protocol to prospectively investigate the effects of GAHT in trans people. Since then, we have collaborated on a workshop about GAHT outcomes at the European Professional Association for Transgender Health (EPATH) in April 2019 and wrote a narrative review on feminizing GAHT. I have also submitted a proposal to conduct subgroup analyses on existing ENIGI data to see if/how BMI and age influence various health outcomes in that cohort of patients. I am serving on the U.S. Professional Association for Transgender Health (USPATH) 2019 Conference Scientific Review and Awards Committees, while also part of a symposium on screening tests in trans people.
I have ongoing support of my mentorship committee and the CUSOM Department of Medicine, Division of Endocrinology, Metabolism & Diabetes to help achieve their vision of cultivating interdisciplinary trans research. Though early in my career, I have already established myself as a physician advocate dedicated to improving health care/outcomes for trans patients through interdisciplinary clinical translational research and international collaboration, with a focus on obesity and aging.
Dates of Funding: 2019-2020
Transgender (trans) people have a gender identity and/or gender expression that does not align with their sex assigned at birth (SAB). Many trans people experience associated distress known as gender dysphoria. Health care disparities among trans people are prevalent, related to gender dysphoria, fears of discrimination, access to medical/surgical care and other barriers. Among the many health care disparities faced by trans people, studies have reported on decreased physical activity and healthy eating habits as well as increased tobacco smoking, alcohol use and drug use. My quality improvement project during endocrine fellowship revealed higher rates of obesity among both trans women and trans men compared to the general adult population of Colorado. Research locally and around the world tries to better understand the basis for and evaluate solutions to reduce differential health outcomes based on gender identity.
As an early career endocrinologist at the University of Colorado School of Medicine (CUSOM), my academic trajectory is to explore the impacts of obesity, aging and gender-affirming hormone therapy (GAHT, or using sex hormones of the affirmed gender) on cardiometabolic risk in trans people. My current research compares vascular endothelial function and aging in trans women and men on chronic GAHT with the same parameters in cisgender (cis) women and men, individuals whose gender identity aligns with their SAB. These data will provide preliminary data for further investigations on the effects of sex steroids in trans and cis people. My interest in trans research has a foundation in years of volunteer work within the trans and other sexual/gender minority communities. Over the years, I have also heard from trans patients about continued stigma within medicine regarding access to culturally sensitive and comprehensive care. Trans patients deserve evidence-based best practices for health care delivery, particularly in the setting of GAHT, which has been associated with weight gain and an increased risk cardiovascular disease (CVD) and venous thromboembolism in trans women and possibly trans men. Whether gonadectomy (after GAHT, based on clinical practice guidelines) affects CVD risk is yet to be determined.
In September 2017, I co-founded the UCHealth Integrated Transgender Program (ITP) with my mentor, Dr. Micol Rothman, and other specialists in psychiatry, internal medicine, gynecology and plastics and reconstructive surgery, to provide safe and comprehensive care to our trans patients during a single clinic visit within the Endocrinology Clinic. ITP also educates providers, staff and learners across the hospital system and within the community. We received a 2018 University of Colorado President’s Diversity & Inclusive Excellence Grant, the 2019 University of Colorado Hospital Medical Staff Award for Excellence in Clinical Innovation and a 2019 One Colorado Ally Award. We are collecting qualitative (e.g., patient and provider needs assessments) and quantitative (e.g., Pap test and other cancer screening compliance, hormone monitoring, body mass index [BMI] and body composition changes, laboratory trends, pre-/post-Provider Education Day knowledge differences) data. We are establishing a Community Advisory Board to engage stakeholders in developing ideas for future research collaborations and participant recruitment. I am also spearheading the creation of a registry of trans patients at UCHealth and will collect prospective data on health outcomes. Working with the Division of Plastic and Reconstructive Surgery, a new plastic surgeon will join the ITP team in Sept 2019, increasing access to gender-affirming surgery to our patients.
To learn more about trans health research, I met Dr. Guy T’Sjoen (Ghent University Hospital, Belgium) and Dr. Martin den Heijer (Amsterdam University Medical Center, the Netherlands) as part of a 2017 American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) Dr. Lewis E. Braverman Educational Fund Travel Grant. Both are endocrinologists and primary investigators of the European Network for the Investigation of Gender Incongruence (ENIGI), the first collaboration to create a multicenter, multinational, standardized treatment and follow up protocol to prospectively investigate the effects of GAHT in trans people. Since then, we have collaborated on a workshop about GAHT outcomes at the European Professional Association for Transgender Health (EPATH) in April 2019 and wrote a narrative review on feminizing GAHT. I have also submitted a proposal to conduct subgroup analyses on existing ENIGI data to see if/how BMI and age influence various health outcomes in that cohort of patients. I am serving on the U.S. Professional Association for Transgender Health (USPATH) 2019 Conference Scientific Review and Awards Committees, while also part of a symposium on screening tests in trans people.
I have ongoing support of my mentorship committee and the CUSOM Department of Medicine, Division of Endocrinology, Metabolism & Diabetes to help achieve their vision of cultivating interdisciplinary trans research. Though early in my career, I have already established myself as a physician advocate dedicated to improving health care/outcomes for trans patients through interdisciplinary clinical translational research and international collaboration, with a focus on obesity and aging.
Dates of Funding: 2019-2020
Transgender (trans) people have a gender identity and/or gender expression that does not align with their sex assigned at birth (SAB). Many trans people experience associated distress known as gender dysphoria. Health care disparities among trans people are prevalent, related to gender dysphoria, fears of discrimination, access to medical/surgical care and other barriers. Among the many health care disparities faced by trans people, studies have reported on decreased physical activity and healthy eating habits as well as increased tobacco smoking, alcohol use and drug use. My quality improvement project during endocrine fellowship revealed higher rates of obesity among both trans women and trans men compared to the general adult population of Colorado. Research locally and around the world tries to better understand the basis for and evaluate solutions to reduce differential health outcomes based on gender identity.
As an early career endocrinologist at the University of Colorado School of Medicine (CUSOM), my academic trajectory is to explore the impacts of obesity, aging and gender-affirming hormone therapy (GAHT, or using sex hormones of the affirmed gender) on cardiometabolic risk in trans people. My current research compares vascular endothelial function and aging in trans women and men on chronic GAHT with the same parameters in cisgender (cis) women and men, individuals whose gender identity aligns with their SAB. These data will provide preliminary data for further investigations on the effects of sex steroids in trans and cis people. My interest in trans research has a foundation in years of volunteer work within the trans and other sexual/gender minority communities. Over the years, I have also heard from trans patients about continued stigma within medicine regarding access to culturally sensitive and comprehensive care. Trans patients deserve evidence-based best practices for health care delivery, particularly in the setting of GAHT, which has been associated with weight gain and an increased risk cardiovascular disease (CVD) and venous thromboembolism in trans women and possibly trans men. Whether gonadectomy (after GAHT, based on clinical practice guidelines) affects CVD risk is yet to be determined.
In September 2017, I co-founded the UCHealth Integrated Transgender Program (ITP) with my mentor, Dr. Micol Rothman, and other specialists in psychiatry, internal medicine, gynecology and plastics and reconstructive surgery, to provide safe and comprehensive care to our trans patients during a single clinic visit within the Endocrinology Clinic. ITP also educates providers, staff and learners across the hospital system and within the community. We received a 2018 University of Colorado President’s Diversity & Inclusive Excellence Grant, the 2019 University of Colorado Hospital Medical Staff Award for Excellence in Clinical Innovation and a 2019 One Colorado Ally Award. We are collecting qualitative (e.g., patient and provider needs assessments) and quantitative (e.g., Pap test and other cancer screening compliance, hormone monitoring, body mass index [BMI] and body composition changes, laboratory trends, pre-/post-Provider Education Day knowledge differences) data. We are establishing a Community Advisory Board to engage stakeholders in developing ideas for future research collaborations and participant recruitment. I am also spearheading the creation of a registry of trans patients at UCHealth and will collect prospective data on health outcomes. Working with the Division of Plastic and Reconstructive Surgery, a new plastic surgeon will join the ITP team in Sept 2019, increasing access to gender-affirming surgery to our patients.
To learn more about trans health research, I met Dr. Guy T’Sjoen (Ghent University Hospital, Belgium) and Dr. Martin den Heijer (Amsterdam University Medical Center, the Netherlands) as part of a 2017 American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) Dr. Lewis E. Braverman Educational Fund Travel Grant. Both are endocrinologists and primary investigators of the European Network for the Investigation of Gender Incongruence (ENIGI), the first collaboration to create a multicenter, multinational, standardized treatment and follow up protocol to prospectively investigate the effects of GAHT in trans people. Since then, we have collaborated on a workshop about GAHT outcomes at the European Professional Association for Transgender Health (EPATH) in April 2019 and wrote a narrative review on feminizing GAHT. I have also submitted a proposal to conduct subgroup analyses on existing ENIGI data to see if/how BMI and age influence various health outcomes in that cohort of patients. I am serving on the U.S. Professional Association for Transgender Health (USPATH) 2019 Conference Scientific Review and Awards Committees, while also part of a symposium on screening tests in trans people.
I have ongoing support of my mentorship committee and the CUSOM Department of Medicine, Division of Endocrinology, Metabolism & Diabetes to help achieve their vision of cultivating interdisciplinary trans research. Though early in my career, I have already established myself as a physician advocate dedicated to improving health care/outcomes for trans patients through interdisciplinary clinical translational research and international collaboration, with a focus on obesity and aging.
Dates of Funding: 2019-2020
Transgender (trans) people have a gender identity and/or gender expression that does not align with their sex assigned at birth (SAB). Many trans people experience associated distress known as gender dysphoria. Health care disparities among trans people are prevalent, related to gender dysphoria, fears of discrimination, access to medical/surgical care and other barriers. Among the many health care disparities faced by trans people, studies have reported on decreased physical activity and healthy eating habits as well as increased tobacco smoking, alcohol use and drug use. My quality improvement project during endocrine fellowship revealed higher rates of obesity among both trans women and trans men compared to the general adult population of Colorado. Research locally and around the world tries to better understand the basis for and evaluate solutions to reduce differential health outcomes based on gender identity.
As an early career endocrinologist at the University of Colorado School of Medicine (CUSOM), my academic trajectory is to explore the impacts of obesity, aging and gender-affirming hormone therapy (GAHT, or using sex hormones of the affirmed gender) on cardiometabolic risk in trans people. My current research compares vascular endothelial function and aging in trans women and men on chronic GAHT with the same parameters in cisgender (cis) women and men, individuals whose gender identity aligns with their SAB. These data will provide preliminary data for further investigations on the effects of sex steroids in trans and cis people. My interest in trans research has a foundation in years of volunteer work within the trans and other sexual/gender minority communities. Over the years, I have also heard from trans patients about continued stigma within medicine regarding access to culturally sensitive and comprehensive care. Trans patients deserve evidence-based best practices for health care delivery, particularly in the setting of GAHT, which has been associated with weight gain and an increased risk cardiovascular disease (CVD) and venous thromboembolism in trans women and possibly trans men. Whether gonadectomy (after GAHT, based on clinical practice guidelines) affects CVD risk is yet to be determined.
In September 2017, I co-founded the UCHealth Integrated Transgender Program (ITP) with my mentor, Dr. Micol Rothman, and other specialists in psychiatry, internal medicine, gynecology and plastics and reconstructive surgery, to provide safe and comprehensive care to our trans patients during a single clinic visit within the Endocrinology Clinic. ITP also educates providers, staff and learners across the hospital system and within the community. We received a 2018 University of Colorado President’s Diversity & Inclusive Excellence Grant, the 2019 University of Colorado Hospital Medical Staff Award for Excellence in Clinical Innovation and a 2019 One Colorado Ally Award. We are collecting qualitative (e.g., patient and provider needs assessments) and quantitative (e.g., Pap test and other cancer screening compliance, hormone monitoring, body mass index [BMI] and body composition changes, laboratory trends, pre-/post-Provider Education Day knowledge differences) data. We are establishing a Community Advisory Board to engage stakeholders in developing ideas for future research collaborations and participant recruitment. I am also spearheading the creation of a registry of trans patients at UCHealth and will collect prospective data on health outcomes. Working with the Division of Plastic and Reconstructive Surgery, a new plastic surgeon will join the ITP team in Sept 2019, increasing access to gender-affirming surgery to our patients.
To learn more about trans health research, I met Dr. Guy T’Sjoen (Ghent University Hospital, Belgium) and Dr. Martin den Heijer (Amsterdam University Medical Center, the Netherlands) as part of a 2017 American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) Dr. Lewis E. Braverman Educational Fund Travel Grant. Both are endocrinologists and primary investigators of the European Network for the Investigation of Gender Incongruence (ENIGI), the first collaboration to create a multicenter, multinational, standardized treatment and follow up protocol to prospectively investigate the effects of GAHT in trans people. Since then, we have collaborated on a workshop about GAHT outcomes at the European Professional Association for Transgender Health (EPATH) in April 2019 and wrote a narrative review on feminizing GAHT. I have also submitted a proposal to conduct subgroup analyses on existing ENIGI data to see if/how BMI and age influence various health outcomes in that cohort of patients. I am serving on the U.S. Professional Association for Transgender Health (USPATH) 2019 Conference Scientific Review and Awards Committees, while also part of a symposium on screening tests in trans people.
I have ongoing support of my mentorship committee and the CUSOM Department of Medicine, Division of Endocrinology, Metabolism & Diabetes to help achieve their vision of cultivating interdisciplinary trans research. Though early in my career, I have already established myself as a physician advocate dedicated to improving health care/outcomes for trans patients through interdisciplinary clinical translational research and international collaboration, with a focus on obesity and aging.
Dates of Funding: 2019-2020
Transgender (trans) people have a gender identity and/or gender expression that does not align with their sex assigned at birth (SAB). Many trans people experience associated distress known as gender dysphoria. Health care disparities among trans people are prevalent, related to gender dysphoria, fears of discrimination, access to medical/surgical care and other barriers. Among the many health care disparities faced by trans people, studies have reported on decreased physical activity and healthy eating habits as well as increased tobacco smoking, alcohol use and drug use. My quality improvement project during endocrine fellowship revealed higher rates of obesity among both trans women and trans men compared to the general adult population of Colorado. Research locally and around the world tries to better understand the basis for and evaluate solutions to reduce differential health outcomes based on gender identity.
As an early career endocrinologist at the University of Colorado School of Medicine (CUSOM), my academic trajectory is to explore the impacts of obesity, aging and gender-affirming hormone therapy (GAHT, or using sex hormones of the affirmed gender) on cardiometabolic risk in trans people. My current research compares vascular endothelial function and aging in trans women and men on chronic GAHT with the same parameters in cisgender (cis) women and men, individuals whose gender identity aligns with their SAB. These data will provide preliminary data for further investigations on the effects of sex steroids in trans and cis people. My interest in trans research has a foundation in years of volunteer work within the trans and other sexual/gender minority communities. Over the years, I have also heard from trans patients about continued stigma within medicine regarding access to culturally sensitive and comprehensive care. Trans patients deserve evidence-based best practices for health care delivery, particularly in the setting of GAHT, which has been associated with weight gain and an increased risk cardiovascular disease (CVD) and venous thromboembolism in trans women and possibly trans men. Whether gonadectomy (after GAHT, based on clinical practice guidelines) affects CVD risk is yet to be determined.
In September 2017, I co-founded the UCHealth Integrated Transgender Program (ITP) with my mentor, Dr. Micol Rothman, and other specialists in psychiatry, internal medicine, gynecology and plastics and reconstructive surgery, to provide safe and comprehensive care to our trans patients during a single clinic visit within the Endocrinology Clinic. ITP also educates providers, staff and learners across the hospital system and within the community. We received a 2018 University of Colorado President’s Diversity & Inclusive Excellence Grant, the 2019 University of Colorado Hospital Medical Staff Award for Excellence in Clinical Innovation and a 2019 One Colorado Ally Award. We are collecting qualitative (e.g., patient and provider needs assessments) and quantitative (e.g., Pap test and other cancer screening compliance, hormone monitoring, body mass index [BMI] and body composition changes, laboratory trends, pre-/post-Provider Education Day knowledge differences) data. We are establishing a Community Advisory Board to engage stakeholders in developing ideas for future research collaborations and participant recruitment. I am also spearheading the creation of a registry of trans patients at UCHealth and will collect prospective data on health outcomes. Working with the Division of Plastic and Reconstructive Surgery, a new plastic surgeon will join the ITP team in Sept 2019, increasing access to gender-affirming surgery to our patients.
To learn more about trans health research, I met Dr. Guy T’Sjoen (Ghent University Hospital, Belgium) and Dr. Martin den Heijer (Amsterdam University Medical Center, the Netherlands) as part of a 2017 American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) Dr. Lewis E. Braverman Educational Fund Travel Grant. Both are endocrinologists and primary investigators of the European Network for the Investigation of Gender Incongruence (ENIGI), the first collaboration to create a multicenter, multinational, standardized treatment and follow up protocol to prospectively investigate the effects of GAHT in trans people. Since then, we have collaborated on a workshop about GAHT outcomes at the European Professional Association for Transgender Health (EPATH) in April 2019 and wrote a narrative review on feminizing GAHT. I have also submitted a proposal to conduct subgroup analyses on existing ENIGI data to see if/how BMI and age influence various health outcomes in that cohort of patients. I am serving on the U.S. Professional Association for Transgender Health (USPATH) 2019 Conference Scientific Review and Awards Committees, while also part of a symposium on screening tests in trans people.
I have ongoing support of my mentorship committee and the CUSOM Department of Medicine, Division of Endocrinology, Metabolism & Diabetes to help achieve their vision of cultivating interdisciplinary trans research. Though early in my career, I have already established myself as a physician advocate dedicated to improving health care/outcomes for trans patients through interdisciplinary clinical translational research and international collaboration, with a focus on obesity and aging.
Dates of Funding: 2019-2020
Transgender (trans) people have a gender identity and/or gender expression that does not align with their sex assigned at birth (SAB). Many trans people experience associated distress known as gender dysphoria. Health care disparities among trans people are prevalent, related to gender dysphoria, fears of discrimination, access to medical/surgical care and other barriers. Among the many health care disparities faced by trans people, studies have reported on decreased physical activity and healthy eating habits as well as increased tobacco smoking, alcohol use and drug use. My quality improvement project during endocrine fellowship revealed higher rates of obesity among both trans women and trans men compared to the general adult population of Colorado. Research locally and around the world tries to better understand the basis for and evaluate solutions to reduce differential health outcomes based on gender identity.
As an early career endocrinologist at the University of Colorado School of Medicine (CUSOM), my academic trajectory is to explore the impacts of obesity, aging and gender-affirming hormone therapy (GAHT, or using sex hormones of the affirmed gender) on cardiometabolic risk in trans people. My current research compares vascular endothelial function and aging in trans women and men on chronic GAHT with the same parameters in cisgender (cis) women and men, individuals whose gender identity aligns with their SAB. These data will provide preliminary data for further investigations on the effects of sex steroids in trans and cis people. My interest in trans research has a foundation in years of volunteer work within the trans and other sexual/gender minority communities. Over the years, I have also heard from trans patients about continued stigma within medicine regarding access to culturally sensitive and comprehensive care. Trans patients deserve evidence-based best practices for health care delivery, particularly in the setting of GAHT, which has been associated with weight gain and an increased risk cardiovascular disease (CVD) and venous thromboembolism in trans women and possibly trans men. Whether gonadectomy (after GAHT, based on clinical practice guidelines) affects CVD risk is yet to be determined.
In September 2017, I co-founded the UCHealth Integrated Transgender Program (ITP) with my mentor, Dr. Micol Rothman, and other specialists in psychiatry, internal medicine, gynecology and plastics and reconstructive surgery, to provide safe and comprehensive care to our trans patients during a single clinic visit within the Endocrinology Clinic. ITP also educates providers, staff and learners across the hospital system and within the community. We received a 2018 University of Colorado President’s Diversity & Inclusive Excellence Grant, the 2019 University of Colorado Hospital Medical Staff Award for Excellence in Clinical Innovation and a 2019 One Colorado Ally Award. We are collecting qualitative (e.g., patient and provider needs assessments) and quantitative (e.g., Pap test and other cancer screening compliance, hormone monitoring, body mass index [BMI] and body composition changes, laboratory trends, pre-/post-Provider Education Day knowledge differences) data. We are establishing a Community Advisory Board to engage stakeholders in developing ideas for future research collaborations and participant recruitment. I am also spearheading the creation of a registry of trans patients at UCHealth and will collect prospective data on health outcomes. Working with the Division of Plastic and Reconstructive Surgery, a new plastic surgeon will join the ITP team in Sept 2019, increasing access to gender-affirming surgery to our patients.
To learn more about trans health research, I met Dr. Guy T’Sjoen (Ghent University Hospital, Belgium) and Dr. Martin den Heijer (Amsterdam University Medical Center, the Netherlands) as part of a 2017 American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) Dr. Lewis E. Braverman Educational Fund Travel Grant. Both are endocrinologists and primary investigators of the European Network for the Investigation of Gender Incongruence (ENIGI), the first collaboration to create a multicenter, multinational, standardized treatment and follow up protocol to prospectively investigate the effects of GAHT in trans people. Since then, we have collaborated on a workshop about GAHT outcomes at the European Professional Association for Transgender Health (EPATH) in April 2019 and wrote a narrative review on feminizing GAHT. I have also submitted a proposal to conduct subgroup analyses on existing ENIGI data to see if/how BMI and age influence various health outcomes in that cohort of patients. I am serving on the U.S. Professional Association for Transgender Health (USPATH) 2019 Conference Scientific Review and Awards Committees, while also part of a symposium on screening tests in trans people.
I have ongoing support of my mentorship committee and the CUSOM Department of Medicine, Division of Endocrinology, Metabolism & Diabetes to help achieve their vision of cultivating interdisciplinary trans research. Though early in my career, I have already established myself as a physician advocate dedicated to improving health care/outcomes for trans patients through interdisciplinary clinical translational research and international collaboration, with a focus on obesity and aging.
Dates of Funding: 2019-2020
Transgender (trans) people have a gender identity and/or gender expression that does not align with their sex assigned at birth (SAB). Many trans people experience associated distress known as gender dysphoria. Health care disparities among trans people are prevalent, related to gender dysphoria, fears of discrimination, access to medical/surgical care and other barriers. Among the many health care disparities faced by trans people, studies have reported on decreased physical activity and healthy eating habits as well as increased tobacco smoking, alcohol use and drug use. My quality improvement project during endocrine fellowship revealed higher rates of obesity among both trans women and trans men compared to the general adult population of Colorado. Research locally and around the world tries to better understand the basis for and evaluate solutions to reduce differential health outcomes based on gender identity.
As an early career endocrinologist at the University of Colorado School of Medicine (CUSOM), my academic trajectory is to explore the impacts of obesity, aging and gender-affirming hormone therapy (GAHT, or using sex hormones of the affirmed gender) on cardiometabolic risk in trans people. My current research compares vascular endothelial function and aging in trans women and men on chronic GAHT with the same parameters in cisgender (cis) women and men, individuals whose gender identity aligns with their SAB. These data will provide preliminary data for further investigations on the effects of sex steroids in trans and cis people. My interest in trans research has a foundation in years of volunteer work within the trans and other sexual/gender minority communities. Over the years, I have also heard from trans patients about continued stigma within medicine regarding access to culturally sensitive and comprehensive care. Trans patients deserve evidence-based best practices for health care delivery, particularly in the setting of GAHT, which has been associated with weight gain and an increased risk cardiovascular disease (CVD) and venous thromboembolism in trans women and possibly trans men. Whether gonadectomy (after GAHT, based on clinical practice guidelines) affects CVD risk is yet to be determined.
In September 2017, I co-founded the UCHealth Integrated Transgender Program (ITP) with my mentor, Dr. Micol Rothman, and other specialists in psychiatry, internal medicine, gynecology and plastics and reconstructive surgery, to provide safe and comprehensive care to our trans patients during a single clinic visit within the Endocrinology Clinic. ITP also educates providers, staff and learners across the hospital system and within the community. We received a 2018 University of Colorado President’s Diversity & Inclusive Excellence Grant, the 2019 University of Colorado Hospital Medical Staff Award for Excellence in Clinical Innovation and a 2019 One Colorado Ally Award. We are collecting qualitative (e.g., patient and provider needs assessments) and quantitative (e.g., Pap test and other cancer screening compliance, hormone monitoring, body mass index [BMI] and body composition changes, laboratory trends, pre-/post-Provider Education Day knowledge differences) data. We are establishing a Community Advisory Board to engage stakeholders in developing ideas for future research collaborations and participant recruitment. I am also spearheading the creation of a registry of trans patients at UCHealth and will collect prospective data on health outcomes. Working with the Division of Plastic and Reconstructive Surgery, a new plastic surgeon will join the ITP team in Sept 2019, increasing access to gender-affirming surgery to our patients.
To learn more about trans health research, I met Dr. Guy T’Sjoen (Ghent University Hospital, Belgium) and Dr. Martin den Heijer (Amsterdam University Medical Center, the Netherlands) as part of a 2017 American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) Dr. Lewis E. Braverman Educational Fund Travel Grant. Both are endocrinologists and primary investigators of the European Network for the Investigation of Gender Incongruence (ENIGI), the first collaboration to create a multicenter, multinational, standardized treatment and follow up protocol to prospectively investigate the effects of GAHT in trans people. Since then, we have collaborated on a workshop about GAHT outcomes at the European Professional Association for Transgender Health (EPATH) in April 2019 and wrote a narrative review on feminizing GAHT. I have also submitted a proposal to conduct subgroup analyses on existing ENIGI data to see if/how BMI and age influence various health outcomes in that cohort of patients. I am serving on the U.S. Professional Association for Transgender Health (USPATH) 2019 Conference Scientific Review and Awards Committees, while also part of a symposium on screening tests in trans people.
I have ongoing support of my mentorship committee and the CUSOM Department of Medicine, Division of Endocrinology, Metabolism & Diabetes to help achieve their vision of cultivating interdisciplinary trans research. Though early in my career, I have already established myself as a physician advocate dedicated to improving health care/outcomes for trans patients through interdisciplinary clinical translational research and international collaboration, with a focus on obesity and aging.
Dates of Funding: 2019-2020
Transgender (trans) people have a gender identity and/or gender expression that does not align with their sex assigned at birth (SAB). Many trans people experience associated distress known as gender dysphoria. Health care disparities among trans people are prevalent, related to gender dysphoria, fears of discrimination, access to medical/surgical care and other barriers. Among the many health care disparities faced by trans people, studies have reported on decreased physical activity and healthy eating habits as well as increased tobacco smoking, alcohol use and drug use. My quality improvement project during endocrine fellowship revealed higher rates of obesity among both trans women and trans men compared to the general adult population of Colorado. Research locally and around the world tries to better understand the basis for and evaluate solutions to reduce differential health outcomes based on gender identity.
As an early career endocrinologist at the University of Colorado School of Medicine (CUSOM), my academic trajectory is to explore the impacts of obesity, aging and gender-affirming hormone therapy (GAHT, or using sex hormones of the affirmed gender) on cardiometabolic risk in trans people. My current research compares vascular endothelial function and aging in trans women and men on chronic GAHT with the same parameters in cisgender (cis) women and men, individuals whose gender identity aligns with their SAB. These data will provide preliminary data for further investigations on the effects of sex steroids in trans and cis people. My interest in trans research has a foundation in years of volunteer work within the trans and other sexual/gender minority communities. Over the years, I have also heard from trans patients about continued stigma within medicine regarding access to culturally sensitive and comprehensive care. Trans patients deserve evidence-based best practices for health care delivery, particularly in the setting of GAHT, which has been associated with weight gain and an increased risk cardiovascular disease (CVD) and venous thromboembolism in trans women and possibly trans men. Whether gonadectomy (after GAHT, based on clinical practice guidelines) affects CVD risk is yet to be determined.
In September 2017, I co-founded the UCHealth Integrated Transgender Program (ITP) with my mentor, Dr. Micol Rothman, and other specialists in psychiatry, internal medicine, gynecology and plastics and reconstructive surgery, to provide safe and comprehensive care to our trans patients during a single clinic visit within the Endocrinology Clinic. ITP also educates providers, staff and learners across the hospital system and within the community. We received a 2018 University of Colorado President’s Diversity & Inclusive Excellence Grant, the 2019 University of Colorado Hospital Medical Staff Award for Excellence in Clinical Innovation and a 2019 One Colorado Ally Award. We are collecting qualitative (e.g., patient and provider needs assessments) and quantitative (e.g., Pap test and other cancer screening compliance, hormone monitoring, body mass index [BMI] and body composition changes, laboratory trends, pre-/post-Provider Education Day knowledge differences) data. We are establishing a Community Advisory Board to engage stakeholders in developing ideas for future research collaborations and participant recruitment. I am also spearheading the creation of a registry of trans patients at UCHealth and will collect prospective data on health outcomes. Working with the Division of Plastic and Reconstructive Surgery, a new plastic surgeon will join the ITP team in Sept 2019, increasing access to gender-affirming surgery to our patients.
To learn more about trans health research, I met Dr. Guy T’Sjoen (Ghent University Hospital, Belgium) and Dr. Martin den Heijer (Amsterdam University Medical Center, the Netherlands) as part of a 2017 American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) Dr. Lewis E. Braverman Educational Fund Travel Grant. Both are endocrinologists and primary investigators of the European Network for the Investigation of Gender Incongruence (ENIGI), the first collaboration to create a multicenter, multinational, standardized treatment and follow up protocol to prospectively investigate the effects of GAHT in trans people. Since then, we have collaborated on a workshop about GAHT outcomes at the European Professional Association for Transgender Health (EPATH) in April 2019 and wrote a narrative review on feminizing GAHT. I have also submitted a proposal to conduct subgroup analyses on existing ENIGI data to see if/how BMI and age influence various health outcomes in that cohort of patients. I am serving on the U.S. Professional Association for Transgender Health (USPATH) 2019 Conference Scientific Review and Awards Committees, while also part of a symposium on screening tests in trans people.
I have ongoing support of my mentorship committee and the CUSOM Department of Medicine, Division of Endocrinology, Metabolism & Diabetes to help achieve their vision of cultivating interdisciplinary trans research. Though early in my career, I have already established myself as a physician advocate dedicated to improving health care/outcomes for trans patients through interdisciplinary clinical translational research and international collaboration, with a focus on obesity and aging.
Dates of Funding: 2019-2020
Transgender (trans) people have a gender identity and/or gender expression that does not align with their sex assigned at birth (SAB). Many trans people experience associated distress known as gender dysphoria. Health care disparities among trans people are prevalent, related to gender dysphoria, fears of discrimination, access to medical/surgical care and other barriers. Among the many health care disparities faced by trans people, studies have reported on decreased physical activity and healthy eating habits as well as increased tobacco smoking, alcohol use and drug use. My quality improvement project during endocrine fellowship revealed higher rates of obesity among both trans women and trans men compared to the general adult population of Colorado. Research locally and around the world tries to better understand the basis for and evaluate solutions to reduce differential health outcomes based on gender identity.
As an early career endocrinologist at the University of Colorado School of Medicine (CUSOM), my academic trajectory is to explore the impacts of obesity, aging and gender-affirming hormone therapy (GAHT, or using sex hormones of the affirmed gender) on cardiometabolic risk in trans people. My current research compares vascular endothelial function and aging in trans women and men on chronic GAHT with the same parameters in cisgender (cis) women and men, individuals whose gender identity aligns with their SAB. These data will provide preliminary data for further investigations on the effects of sex steroids in trans and cis people. My interest in trans research has a foundation in years of volunteer work within the trans and other sexual/gender minority communities. Over the years, I have also heard from trans patients about continued stigma within medicine regarding access to culturally sensitive and comprehensive care. Trans patients deserve evidence-based best practices for health care delivery, particularly in the setting of GAHT, which has been associated with weight gain and an increased risk cardiovascular disease (CVD) and venous thromboembolism in trans women and possibly trans men. Whether gonadectomy (after GAHT, based on clinical practice guidelines) affects CVD risk is yet to be determined.
In September 2017, I co-founded the UCHealth Integrated Transgender Program (ITP) with my mentor, Dr. Micol Rothman, and other specialists in psychiatry, internal medicine, gynecology and plastics and reconstructive surgery, to provide safe and comprehensive care to our trans patients during a single clinic visit within the Endocrinology Clinic. ITP also educates providers, staff and learners across the hospital system and within the community. We received a 2018 University of Colorado President’s Diversity & Inclusive Excellence Grant, the 2019 University of Colorado Hospital Medical Staff Award for Excellence in Clinical Innovation and a 2019 One Colorado Ally Award. We are collecting qualitative (e.g., patient and provider needs assessments) and quantitative (e.g., Pap test and other cancer screening compliance, hormone monitoring, body mass index [BMI] and body composition changes, laboratory trends, pre-/post-Provider Education Day knowledge differences) data. We are establishing a Community Advisory Board to engage stakeholders in developing ideas for future research collaborations and participant recruitment. I am also spearheading the creation of a registry of trans patients at UCHealth and will collect prospective data on health outcomes. Working with the Division of Plastic and Reconstructive Surgery, a new plastic surgeon will join the ITP team in Sept 2019, increasing access to gender-affirming surgery to our patients.
To learn more about trans health research, I met Dr. Guy T’Sjoen (Ghent University Hospital, Belgium) and Dr. Martin den Heijer (Amsterdam University Medical Center, the Netherlands) as part of a 2017 American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) Dr. Lewis E. Braverman Educational Fund Travel Grant. Both are endocrinologists and primary investigators of the European Network for the Investigation of Gender Incongruence (ENIGI), the first collaboration to create a multicenter, multinational, standardized treatment and follow up protocol to prospectively investigate the effects of GAHT in trans people. Since then, we have collaborated on a workshop about GAHT outcomes at the European Professional Association for Transgender Health (EPATH) in April 2019 and wrote a narrative review on feminizing GAHT. I have also submitted a proposal to conduct subgroup analyses on existing ENIGI data to see if/how BMI and age influence various health outcomes in that cohort of patients. I am serving on the U.S. Professional Association for Transgender Health (USPATH) 2019 Conference Scientific Review and Awards Committees, while also part of a symposium on screening tests in trans people.
I have ongoing support of my mentorship committee and the CUSOM Department of Medicine, Division of Endocrinology, Metabolism & Diabetes to help achieve their vision of cultivating interdisciplinary trans research. Though early in my career, I have already established myself as a physician advocate dedicated to improving health care/outcomes for trans patients through interdisciplinary clinical translational research and international collaboration, with a focus on obesity and aging.